Table 1.
Patient demographics and baseline disease state
| Baseline Hemoglobin < 10 g/dL | Baseline Hemoglobin ≥10 g/dL | |||||
|---|---|---|---|---|---|---|
| Darbepoetin alfa 500 mcg Q3W N = 176 |
Darbepoetin alfa 2.25 mcg/kg QW N = 175 |
Total N = 351 |
Darbepoetin alfa 500 mcg Q3W N = 177 |
Darbepoetin alfa 2.25 mcg/kg QW N = 177 |
Total N = 354 |
|
| Sex, n (%) | ||||||
| Female | 93 (53) | 97 (55) | 190 (54) | 93 (53) | 100 (56) | 193 (55) |
| Age, years | ||||||
| Median (Min, Max) | 59 (20, 86) | 61 (20, 83) | 60 (20, 86) | 61 (20, 85) | 60 (21, 84) | 60.5 (20, 85) |
| ≥65, n (%) | 59 (34) | 65 (37) | 124 (35) | 65 (37) | 65 (37) | 130 (37) |
| ≥75, n (%) | 15 (9) | 14 (8) | 29 (8) | 19 (11) | 12 (7) | 31 (9) |
| Tumor type, n (%) | ||||||
| Large Intestine/Colon | 30 (17) | 16 (9) | 46 (13) | 35 (20) | 35 (20) | 70 (20) |
| Breast | 23 (13) | 27 (15) | 50 (14) | 34 (19) | 28 (16) | 62 (18) |
| NSCLC | 17 (10) | 15 (9) | 32 (9) | 17 (10) | 17 (10) | 34 (10) |
| Disease stage at diagnosis, n (%) | ||||||
| I | 13 (7) | 10 (6) | 23 (7) | 15 (8) | 8 (5) | 23 (6) |
| II | 25 (14) | 38 (22) | 63 (18) | 40 (23) | 37 (21) | 77 (22) |
| III | 53 (30) | 49 (28) | 102 (29) | 42 (24) | 44 (25) | 86 (24) |
| IV | 74 (42) | 62 (35) | 136 (39) | 59 (33) | 71 (40) | 130 (37) |
| Other/Missing or Unknown | 11 (6) | 16 (9) | 27 (8) | 21 (12) | 17 (10) | 38 (11) |
| Prior chemotherapy, n (%) | 169 (96) | 153 (87) | 322 (92) | 162 (92) | 154 (87) | 316 (89) |
| Prior platinum chemotherapy, n (%) | 68 (39) | 59 (34) | 127 (36) | 59 (33) | 63 (36) | 122 (34) |
| Prior radiotherapy, n (%) | 60 (34) | 47 (27) | 107 (30) | 61 (34) | 56 (32) | 117 (33) |
| Prior erythropoietic therapy, n (%)a | 21 (12) | 21 (12) | 42 (12) | 18 (10) | 13 (7) | 31 (9) |
| Baseline hemoglobin, g/dL | ||||||
| Mean (SD) | 9.01 (0.78) | 9.09 (0.64) | 9.05 (0.71) | 10.50 (0.29) | 10.46 (0.30) | 10.48 (0.30) |
| Median (Min, Max) | 9.20 (5.9, 9.9) | 9.20 (6.8, 9.9) | 9.20 (5.9, 9.9) | 10.50 (10.0, 10.9) | 10.50 (10.0, 11.8) | 10.50 (10.0, 11.8) |
Q3W = every three weeks; QW = weekly; Min = minimum; Max = maximum; NSCLC = non-small cell lung cancer; SD = standard deviation
aPrior erythropoietic agents were not administered within 4 weeks of study day 1.